tradit
viral
vaccin
base
inactiv
attenu
pathogen
advanc
molecular
virolog
concert
viral
immunolog
allow
genet
engin
vector
express
sole
viral
antigen
induc
immun
correl
protect
adenovirus
initi
vector
vehicl
gene
therapi
attempt
replac
miss
faulti
gene
adenovir
gene
transfer
larg
unsuccess
experiment
anim
human
volunt
alik
due
innat
adapt
immun
respons
induc
adenovir
antigen
reduc
appeal
gene
replac
vehicl
invit
use
vaccin
carrier
adenovir
vector
attract
candid
transfer
foreign
gene
number
reason
adenovir
genom
well
character
compar
easi
manipul
adenovirus
caus
mild
diseas
immunocompet
human
adult
delet
crucial
region
viral
genom
vector
render
replicationdefect
increas
predict
reduc
unwant
side
effect
adenovirus
broad
tropism
infect
varieti
divid
nondivid
cell
grown
high
titer
tissu
cultur
appli
system
well
mucos
surfac
rel
thermost
facilit
clinic
use
thu
far
effort
focus
vector
deriv
adenoviru
human
serotyp
eventu
use
vaccin
human
bovin
porcin
ovin
adenovirus
explor
veterinari
use
adenovirus
doublestrand
dna
virus
genom
kb
size
amen
easi
manipul
viru
compens
small
genom
encod
polypeptid
dna
strand
altern
splice
use
differ
poli
site
adenovirus
speciesspecif
differ
serotyp
ie
type
virus
crossneutr
antibodi
isol
varieti
mammalian
speci
serotyp
human
serotyp
simian
includ
chimpanze
human
serotyp
studi
extens
divid
six
subgroup
af
b
subdivid
base
sequenc
homolog
abil
agglutin
red
blood
cell
tabl
linear
genom
flank
two
origin
dna
replic
itr
eight
unit
rna
polymeras
iimedi
transcript
fig
genom
carri
five
earli
unit
review
two
unit
express
delay
initi
viral
replic
ix
one
late
unit
l
subdivid
adenovirus
furthermor
encod
one
two
speci
rna
call
virusassoci
va
rna
control
intern
polymeras
iii
promot
unit
locat
next
left
termin
itr
transcrib
first
help
cellular
factor
activ
transcript
viral
gene
delet
render
viru
replicationdefect
stimul
viral
dna
synthesi
dysregul
cellcycl
control
increas
stabil
promot
apoptosi
independ
mechan
play
role
immunoevas
inhibit
activ
need
activ
interferonrespons
gene
protein
promot
apoptosi
protein
antiapoptot
function
polypeptid
turn
host
cell
protein
synthesi
help
stabil
transport
translat
select
viral
rna
earli
gene
product
caus
transform
rodent
cell
notwithstand
adenovirus
associ
malign
human
unit
encod
dnabind
protein
polymeras
essenti
viral
replic
unit
control
nfnbinduc
promot
nonessenti
viru
replic
protein
allow
viru
escap
immunosurveil
reduc
express
major
histocompat
complex
mhc
class
determin
polypeptid
bind
directli
groov
mhc
class
molecul
thu
prevent
bind
peptid
export
cell
surfac
furthermor
protein
associ
tap
therebi
reduc
effici
transport
peptid
deriv
proteolyt
cleavag
de
novo
synthes
viral
protein
cytoplasm
endoplasm
reticulum
associ
mhc
class
molecul
antigen
block
fasmedi
apoptosi
bind
intern
fa
receptor
inactiv
flice
apoptosiscaus
caspas
protein
block
tnf
signal
pathway
thu
prevent
tnfmediat
kill
infect
cell
late
stage
viral
replic
unit
encod
polypeptid
call
adenoviru
death
protein
promot
death
infect
cell
henc
releas
viru
particl
transcript
unit
encod
seven
polypeptid
distinct
open
read
frame
orf
affect
viral
transcript
number
host
cell
function
includ
cell
prolifer
apoptosi
part
promot
degrad
essenti
nuclear
export
viral
rna
bind
unit
oncogen
potenti
adenovirus
subgroup
b
relat
larg
activ
polypeptid
product
latter
concert
inhibit
cellular
dna
repair
system
redistribut
degrad
pertin
cellular
enzym
thu
prevent
format
concatem
endtoend
join
adenovir
genom
adenovirus
human
subgroup
c
e
chimpanze
serotyp
encod
two
va
rna
adenovirus
human
subgroup
deriv
simian
speci
encod
one
va
rna
va
rnaencod
gene
control
intern
promot
transcrib
high
level
polymeras
iii
result
transcript
short
stretch
rna
base
form
doublestrand
hairpinloop
structur
va
rna
essenti
translat
adenovir
gene
inhibit
pkr
pathway
initi
viral
infect
cell
reduc
translat
phosphoryl
ix
gene
product
transcript
transactiv
minor
compon
viral
capsid
increas
virion
stabil
protein
need
assembl
adenoviru
packag
viral
dna
late
transcript
unit
divid
five
subunit
encod
mani
differ
speci
rna
differenti
splice
earli
late
phase
adenoviru
replic
review
product
late
transcript
unit
form
viral
capsid
review
polypeptid
ii
hexon
encod
unit
abund
capsid
protein
hexon
form
thermost
trimer
format
complex
structur
requir
assist
protein
product
transcript
unit
hexon
base
three
conserv
doubl
barrel
top
three
tower
tower
contain
loop
subunit
form
capsid
base
hexon
highli
conserv
adenovir
serotyp
surfac
loop
target
virusneutr
antibodi
variabl
polypeptid
iii
encod
penton
base
pentamer
structur
upon
bind
polypeptid
iv
fiber
trimer
product
assembl
penton
complex
fiber
compos
shaftlik
region
carri
knoblik
domain
distal
end
minor
coat
protein
includ
polypeptid
iiia
vi
viii
xi
stabil
viral
capsid
connect
coat
protein
viral
chromosom
adenovirus
caus
acut
symptomat
persist
asymptomat
infect
differ
serotyp
preferenti
target
distinct
organ
acut
infect
serotyp
commonli
infect
human
subgenu
c
caus
gener
mild
upper
respiratori
infect
children
subgenera
f
trigger
gastrointestin
symptom
adenovirus
lead
seriou
even
fatal
infect
pneumonia
meningioenceph
especi
immunocompromis
individu
children
symptom
caus
chimpanzeederiv
adenovirus
current
explor
vaccin
develop
remain
ill
defin
upon
acut
infect
adenovirus
known
persist
lymphoid
cell
persist
appear
clinic
sequela
link
gene
product
protect
infect
cell
destruct
adapt
immun
system
also
inhibit
apoptosi
confer
surviv
advantag
persist
infect
cell
persist
viral
genom
retain
episom
viru
rescu
albeit
low
effici
lymphat
tissu
year
acut
infect
human
adenoviru
serotyp
ubiquit
infect
children
earli
infanc
infect
virus
studi
extens
common
depend
region
adult
carri
antibodi
develop
vaccin
carrier
less
common
virusneutr
antibodi
viru
detect
depend
region
adult
chimpanze
virus
test
thu
far
establish
common
infect
chimpanze
preval
neither
human
simian
speci
rhesu
macaqu
frequent
use
preclin
vaccin
test
tropism
adenovirus
determin
abil
attach
host
cell
receptor
involv
initi
bind
distal
knob
domain
fiber
host
cell
surfac
molecul
follow
bind
rgd
motif
within
penton
base
v
integrin
review
human
serotyp
adenovirus
initi
bind
coxsacki
adenoviru
receptor
car
express
mani
cell
type
includ
hepatocyt
basolater
surfac
epitheli
cell
endotheli
cell
myoblast
heart
muscl
cell
lymphoid
cell
express
car
nevertheless
provid
reservoir
persist
infect
adenovirus
use
car
car
also
facilit
entri
chimpanzeeorigin
adenoviru
adenovirus
subgroup
b
bind
car
subgroup
adenovirus
includ
associ
complement
regulatori
protein
express
multipl
cell
type
includ
hematopoiet
stem
cell
dendrit
cell
note
express
mice
spermatocyt
viru
subgroup
viru
attach
two
costimulatori
molecul
express
antigenpres
cell
adenovirus
highli
immunogen
activ
innat
immun
system
presum
express
socal
pathogenassoci
molecular
pattern
pamp
pamp
bind
pathogen
recognit
receptor
host
cell
includ
innat
immun
system
thu
initi
product
proinflammatori
cytokin
differenti
immatur
dendrit
cell
profession
antigenpres
cell
system
administr
high
dose
vector
mice
monkey
shown
trigger
rapid
releas
tnfa
accumul
transduc
macrophag
dendrit
cell
lymphat
tissu
adenovirusinduc
matur
dendrit
cell
shown
nfnbdepend
one
studi
describ
activ
dendrit
cell
link
hstrand
region
fiber
knob
anoth
studi
show
activ
dendrit
cell
link
autocrin
tnfamedi
mechan
tnfa
induc
rgd
sequenc
within
penton
base
drove
differenti
immatur
dendrit
cell
adapt
immun
respons
direct
earli
late
antigen
adenoviru
virusneutr
antibodi
induc
adenovir
infect
upon
adenovir
vector
deliveri
primarili
direct
surfac
loop
viral
hexon
although
antibodi
penton
base
fiber
also
neutral
adenoviru
cell
adenovir
antigen
demonstr
human
frequenc
shown
decreas
age
cell
mainli
type
crossreact
differ
adenovir
serotyp
experiment
anim
adenoviru
adenovir
vector
induc
cell
respons
differ
structur
protein
humana
well
mousederiv
cell
crossreact
human
serotyp
well
human
simian
serotyp
would
expect
consid
extens
sequenc
homolog
target
antigen
origin
adenovir
vector
construct
homolog
recombin
cell
cotransfect
purifi
adenovir
genom
delet
restrict
enzym
digest
shuttl
vector
contain
lefthand
itr
enhanc
encapsid
signal
cytomegaloviru
cmv
ie
promot
anoth
suitabl
promot
multiclon
site
insert
gene
interest
poli
signal
follow
sequenc
adenovir
genom
locat
domain
adenovir
vector
gener
socal
molecular
clone
entir
adenovir
genom
includ
itr
carri
bacteri
plasmid
allow
propag
escherichia
coli
fig
sequenc
interest
ligat
directli
molecular
clone
upon
remov
bacteri
sequenc
transfect
suitabl
packag
cell
line
use
molecular
clone
facilit
gener
vector
construct
commerci
avail
kit
also
facilit
eventu
clinic
use
adenovir
vector
deriv
speci
human
adenovirus
isol
chimpanze
gener
vaccin
carrier
chimpanzeederiv
virus
could
potenti
contamin
yet
identifi
pathogen
could
propag
unnot
parallel
adenovir
vector
tissu
cultur
consid
anim
virus
especi
speci
close
relat
human
chimpanze
potenti
cross
human
well
document
simian
immunodefici
viru
use
chimpanzeeorigin
adenovir
vector
gener
exclus
propag
mammalian
cell
line
would
present
unaccept
risk
human
gener
vaccin
vector
molecular
clone
hand
elimin
peril
hidden
contamin
origin
isol
identif
recombin
viral
plaqu
facilit
introduc
gene
herp
simplex
viru
thymidin
kinas
green
fluoresc
protein
hgalactosidas
domain
former
allow
select
recombin
viru
ganciclovir
latter
identif
fluoresc
upon
stain
adenovir
capsid
allow
latitud
regard
length
genom
packag
effici
foreign
sequenc
kb
insert
adenovir
genom
without
necessit
delet
nevertheless
increas
permit
size
insert
modifi
biolog
adenovir
vector
vaccin
construct
gener
base
adenovir
vector
delet
transcript
unit
initi
adenovir
vaccin
vector
delet
encod
gene
product
nonessenti
viru
replic
vector
accommod
addit
kb
foreign
sequenc
promot
potent
immedi
earli
promot
cmv
drive
express
transgen
product
adenovir
vector
replicationcompet
thu
less
predict
replicationdefect
vector
rais
concern
potenti
toxic
especi
use
immunocompromis
patient
children
elderli
argu
replicationcompet
adenovirus
achiev
higher
antigen
load
compar
replicationdefect
vector
thu
result
higher
sustain
transgen
productspecif
immun
respons
direct
sidebysid
comparison
efficaci
replicationdefect
vs
replicationcompet
adenovir
vaccin
carrier
yet
conduct
speci
permit
replic
vector
contain
thu
one
specul
potenti
advantag
vaccin
carrier
replicationcompet
adenovir
vector
encod
remain
adenovir
antigen
addit
transgen
product
ie
vaccin
antigen
adapt
immun
respons
thu
direct
toward
multitud
differ
antigen
neg
affect
desir
immun
respons
vaccin
antigen
competit
mhc
bind
site
cytokin
need
activ
differenti
prolifer
b
cell
furthermor
adenovirus
caus
cell
type
lytic
infect
viral
progeni
assembl
result
apoptot
death
infect
cell
shorten
durat
antigen
present
individu
infect
cell
turn
could
neg
effect
induct
cell
stimul
primarili
peptid
deriv
de
novo
synthes
antigen
potenti
favor
activ
cell
induc
peptid
deriv
lysosom
cleavag
protein
taken
phagocytosi
pinocytosi
although
test
depth
adenovir
vector
experi
poxviru
vector
indic
replic
compet
necessarili
translat
stronger
transgen
productspecif
immun
respons
poxviru
vector
rapidli
produc
larg
amount
transgen
product
nevertheless
induc
compar
adenovir
vector
express
antigen
modest
b
cell
respons
transgen
product
vector
current
use
vaccin
carrier
delet
render
vector
repli
cationdefect
also
allow
sustain
antigen
present
reduc
vector
abil
induc
death
infect
cell
essenti
viral
replic
therefor
provid
tran
product
vector
incorpor
larger
foreign
sequenc
vector
delet
develop
accommod
kb
foreign
dna
vector
addit
delet
thu
far
explor
mainli
gene
therapi
vector
includ
delet
vector
produc
fewer
late
gene
product
compar
vector
thu
reduc
induct
vectorspecif
immun
respons
one
would
also
expect
presenc
preexist
adenovirusspecif
cell
vector
would
provid
lower
amount
target
antigen
tcellmedi
destruct
antigenpres
cell
thu
potenti
increas
durat
present
vaccin
antigen
consequ
magnitud
antigenspecif
immun
respons
remain
test
furthermor
delet
minim
outgrowth
replicationcompet
viru
packag
cell
line
vector
construct
result
lower
yield
compar
construct
vector
delet
vector
lack
viral
gene
develop
gene
therapi
latter
type
construct
commonli
refer
gut
vector
propag
presenc
helper
virus
commonli
contamin
vector
batch
furthermor
gut
adenovir
construct
current
propag
quantiti
need
clinic
develop
vector
destin
mass
vaccin
adenovir
vector
delet
grown
cell
line
suppli
delet
transcript
unit
tran
hek
cell
carri
leftsid
genom
includ
lefthand
itr
cisact
packag
sequenc
protein
ix
sequenc
commonli
use
propag
vector
growth
vector
hek
cell
lead
homolog
recombin
follow
outgrowth
replicationcompet
adenoviru
rca
common
problem
least
part
circumv
altern
packag
cell
line
ie
cell
cell
contain
sequenc
control
human
phosphoglycer
kinas
promot
lack
overlap
sequenc
outsid
transcript
unit
diminish
homolog
recombin
thu
outgrowth
rca
adenovir
vector
chimpanze
serotyp
transcompl
viru
vector
grown
hek
cell
lack
sequenc
homolog
region
prevent
homolog
recombin
henc
outgrowth
rca
chimpanze
adenovir
vector
human
adenovir
vector
base
viru
transcompl
viru
thu
necessit
modif
avail
packag
cell
line
insert
gene
cell
line
carri
viru
altern
construct
serotyp
adenovir
vector
endogen
bind
replac
viru
may
allow
propag
avail
cell
line
provid
viru
tran
propag
adenovir
vector
addit
delet
either
requir
delet
gene
provid
packag
cell
line
helper
viru
delet
suitabl
adenovir
vaccin
carrier
like
depend
number
variabl
type
size
insert
potenti
serotyp
adenoviru
vector
well
growth
characterist
individu
construct
adenovir
vaccin
carrier
progress
toward
clinic
trial
thorough
analysi
effect
variou
delet
growth
properti
genom
stabil
capsid
stabil
seem
warrant
although
packag
allow
latitud
size
adenovir
genom
shown
viru
overli
long
insert
caus
genet
instabl
vector
remain
assess
care
well
less
well
character
serotyp
adenoviru
degre
genom
size
affect
genet
stabil
growth
characterist
thermost
construct
tropism
adenovir
vector
alter
genet
engin
fiber
knob
replac
larg
portion
cterminu
fiber
protein
reoviru
type
share
structur
featur
form
trimer
tripl
h
spiral
motif
head
tail
morpholog
result
stabl
vector
use
reoviru
receptor
junction
adhes
molecul
viral
entri
thu
show
improv
transduct
certain
cell
type
includ
dendrit
cell
express
receptor
vector
pseudotyp
fiber
adenovirus
subgroup
b
c
f
result
vector
reduc
tropism
myoblast
endotheli
cell
fiber
subgroup
b
increas
tropism
dendrit
cell
fiber
subgroup
b
ie
vitro
vivo
without
affect
mice
result
transgen
productspecif
b
cell
respons
anoth
report
fiber
subtyp
c
viru
replac
subtyp
b
fiber
ie
one
deriv
viru
pseudotyp
vector
increas
abil
transduc
dendrit
cell
result
improv
induct
cell
vitro
vivo
upon
transfer
transduc
dendrit
cell
effect
direct
applic
pseudotyp
vector
adapt
immun
investig
insert
rgd
sequenc
fiber
knob
vector
increas
effici
transduc
dendrit
cell
tumor
model
modifi
vector
shown
slightli
efficaci
induc
higher
transgen
productspecif
cell
respons
coat
adenoviru
adaptor
molecul
connect
car
result
increas
transduct
dendrit
cell
enhanc
immun
respons
report
protein
approxim
twoto
fourfold
overal
result
retarget
vector
dendrit
cell
enhanc
antigen
present
remain
inconclus
addit
vivo
test
vector
necessari
assess
util
improv
vaccin
vehicl
quantit
method
test
transgen
productspecif
cell
frequenc
intracellular
cytokin
stain
shown
fig
avail
allow
accur
assess
vaccin
abil
induc
cell
respons
quantit
method
combin
vaccin
titrat
care
kinet
studi
especi
warrant
model
vaccin
efficaci
test
challeng
pathogen
caus
signific
morbid
mortal
experiment
anim
avail
use
assay
also
prerequisit
evalu
potenti
benefit
vector
modif
gene
therapist
attempt
develop
adenovir
vector
replac
faulti
gene
inadvert
pioneer
develop
adenovir
vaccin
carrier
longterm
express
vectorencod
report
protein
hgalactosidas
readili
achiev
lung
liver
immunodefici
mice
contrast
immunocompet
anim
express
transient
vectortransduc
cell
rapidli
clear
within
day
mainli
cell
direct
transgen
product
antigen
adenoviru
abil
vector
induc
except
potent
transgen
productspecif
immun
respons
led
use
vaccin
carrier
rabi
viru
glycoprotein
sole
antigen
rabi
viru
induc
virusneutr
antibodi
known
provid
protect
rabi
viru
challeng
vector
term
adrabgp
induc
rapidli
within
week
protect
titer
neutral
antibodi
well
rabi
virusspecif
cell
replicationcompet
adenovir
vector
express
glycoprotein
close
relat
strain
rabi
viru
perform
compar
poorli
requir
higher
dose
induc
protect
antibodi
titer
studi
rapidli
confirm
pathogen
antigen
tabl
vaccin
vector
express
antigen
clinic
trial
report
experiment
anim
system
describ
similar
find
vector
induc
potent
transgen
productspecif
antibodi
cell
respons
rodent
dog
nonhuman
primat
transgen
productspecif
antibodi
mainli
isotyp
mice
although
also
induc
suggest
mix
respons
predomin
help
adenovir
vector
induc
overli
potent
transgen
productspecif
cell
respons
although
studi
compar
efficaci
adenovir
vector
subunit
vaccin
still
incomplet
avail
data
show
outperform
poxviru
vector
dna
vaccin
alphaviru
vector
regard
induct
transgen
productspecif
antibodi
titer
cell
frequenc
induc
protect
immun
respons
quickli
respons
long
live
induc
adult
well
immunolog
immatur
neonat
mice
antibodi
respons
elicit
upon
system
well
mucos
includ
oral
immun
cell
prime
oral
applic
vector
frequenc
detect
spleen
markedli
lower
upon
system
applic
except
immunogen
vector
like
reflect
abil
activ
cell
innat
immun
system
transduc
immatur
dendrit
cell
drive
matur
antigenpres
cell
achiev
longlast
antigen
present
induc
apoptosi
transduc
cell
express
high
level
transgen
product
driven
vector
potent
cmv
promot
number
differ
antigen
express
vaccin
list
tabl
high
detail
review
thu
restrict
review
limit
number
viral
pathogen
provid
uniqu
challeng
vaccin
develop
may
met
adenovir
vector
vaccin
prevent
infect
induct
neutral
antibodi
pathogen
surfac
antigen
vector
induc
protect
neutral
antibodi
titer
transgen
product
rapidli
singl
applic
shown
initi
rabi
viru
glycoprotein
featur
particularli
use
postexposur
vaccin
combat
infecti
agent
caus
infrequ
rapidli
spread
outbreak
associ
high
mortal
rabi
vaccin
case
given
human
exposur
feasibl
viru
lengthi
albeit
vari
incub
period
minim
day
maxim
sever
decad
case
rabi
viru
transmit
human
bite
rabid
anim
unlik
discreet
exposur
pathogen
direct
patient
attent
seek
medic
help
current
use
rabi
vaccin
base
inactiv
viru
requir
sever
booster
immun
tissu
culturegrown
vaccin
brain
tissuederiv
vaccin
elicit
protect
titer
rabi
virusneutr
antibodi
case
sever
exposur
activ
immun
combin
passiv
immun
rabi
immunoglobulin
rig
human
equin
origin
rig
short
suppli
expens
thu
underutil
despit
highli
effect
treatment
regimen
rabi
still
claim
india
alon
report
death
annual
actual
number
presum
significantli
higher
half
children
age
singledos
rabi
vaccin
abl
elicit
protect
rapidli
would
expect
reduc
need
rig
increas
patient
willing
compli
treatment
suspect
exposur
thu
decreas
mortal
symptomat
rabi
infect
close
vaccin
induc
rodent
suitabl
preclin
model
assess
efficaci
rabi
vaccin
protect
antibodi
titer
within
day
singl
intramuscular
subcutan
applic
moder
dose
vector
protect
titer
rabi
viru
also
induc
intranas
applic
vector
intranas
applic
conveni
vaccin
applic
inject
also
favor
induct
transgen
productspecif
antibodi
iga
isotyp
upon
secret
mucos
surfac
best
suit
prevent
invas
pathogen
airway
gastrointestin
tract
genit
mucosa
nevertheless
intranas
applic
adenovir
vector
carri
potenti
risk
inadvert
transfer
vector
nervou
system
report
shown
upon
intranas
applic
adenoviru
mice
viru
infect
central
nervou
system
adenovir
vector
appli
directli
central
nervou
system
shown
previous
caus
albeit
transient
histopatholog
consist
local
necrosi
gliosi
malacia
astrocytosi
addit
toxic
studi
nonhuman
primat
requir
elucid
potenti
neurotox
intranas
appli
adenovir
vector
oral
applic
vaccin
dilut
buffer
salin
induc
protect
antibodi
titer
adult
well
neonat
mice
nevertheless
rout
applic
requir
signific
dose
escal
may
circumv
formul
previous
use
oral
vaccin
militari
personnel
live
adenoviru
vaccin
serotyp
graph
show
frequenc
transgen
productspecif
cell
induc
adenovir
vector
human
serotyp
bottom
chimpanze
serotyp
top
mice
inject
intramuscularli
vp
vector
ten
day
later
splenocyt
cultur
h
peptid
carri
immunodomin
epitop
transgen
product
right
unrel
peptid
left
presenc
brefeldin
cell
stain
fitclabel
antibodi
upon
permeabil
membran
pelabel
antibodi
interferon
ifng
cell
analyz
twocolor
flow
cytometri
data
analyz
wimndi
softwar
event
gate
onto
live
cell
percentag
doubleposit
cell
cell
produc
ifng
fitcposit
cell
cell
determin
display
upper
right
quadrant
oral
immun
adenovir
vaccin
carrier
may
particularli
desir
limit
natur
outbreak
less
develop
countri
winter
china
report
cluster
case
sever
acut
respiratori
syndrom
sar
suspect
infecti
etiolog
similar
case
soon
report
part
asia
europ
canada
caus
agent
identifi
coronaviru
cross
anim
human
although
outbreak
rapidli
contain
isol
patient
contact
high
morbid
mortal
sar
may
resurfac
yet
identifi
anim
reservoir
make
imper
develop
vaccin
induc
protect
immun
rapidli
singl
dose
vector
express
spike
protein
membran
protein
nucleoprotein
sar
viru
shown
induc
virusneutr
antibodi
cell
respons
nonhuman
primat
vaccin
ebola
viru
filoviru
caus
hemorrhag
fever
high
persontoperson
transmiss
rate
mortal
rate
rang
current
avail
antibodi
direct
viral
glycoprotein
like
provid
protect
ebola
viru
infect
vaccin
express
ebola
glycoprotein
develop
shown
efficaci
nonhuman
primat
ebola
viru
consid
potenti
weapon
mass
destruct
increas
threat
intent
releas
agent
terrorist
group
rogu
nation
drive
develop
new
improv
vaccin
adenovir
vaccin
carrier
due
eas
product
potenti
mucos
administr
speed
induc
protect
titer
antibodi
may
becom
valuabl
tool
contain
morbid
ebola
viru
viral
weapon
introduc
suscept
popul
vaccin
remain
elus
initi
attempt
develop
vaccin
gener
broadli
crossreact
neutral
antibodi
human
immunodefici
viru
hiv
fail
vaccin
current
develop
focu
stimul
cell
notabl
cell
conserv
sequenc
vaccin
express
individu
antigen
siv
envelop
protein
gag
mixtur
antigen
given
either
combin
cocktail
vector
fusion
polypeptid
singl
vector
shown
induc
potent
cell
respons
mice
nonhuman
primat
rhesu
macaqu
gagexpress
vector
provid
protect
challeng
pathogen
chimer
simian
human
immunodefici
viru
prevent
cell
loss
contain
viral
load
although
preclin
test
vector
experiment
anim
yield
uniformli
promis
result
vector
destin
encount
problem
human
subject
unlik
experiment
anim
preexpos
viru
mani
case
especi
children
young
adult
still
harbor
residu
wildtyp
viru
lymphat
tissu
limit
transcript
may
maintain
adapt
immun
respons
antigen
adenoviru
heighten
stage
activ
preexist
immun
due
natur
infect
result
sustain
virusneutr
antibodi
titer
major
handicap
success
use
common
serotyp
adenoviru
includ
carrier
gene
replac
therapi
vaccin
carrier
human
popul
neutral
antibodi
even
present
moder
titer
reduc
uptak
adenovir
vector
cell
includ
antigenpres
cell
thu
express
transgen
product
turn
impact
result
transgen
productspecif
immun
respons
shown
initi
experiment
anim
human
theori
may
overcom
increas
dose
vector
approach
limit
vector
toxic
neutral
antibodi
titer
adenoviru
vari
tremend
individu
gener
higher
children
young
adult
decreas
age
use
common
human
serotyp
adenoviru
vaccin
either
would
requir
prior
test
individu
titer
neutral
antibodi
subsequ
adjust
vaccin
dose
conting
magnitud
titer
would
result
unpredict
immun
respons
circumv
impact
adenovirusspecif
neutral
antibodi
current
major
scientif
focu
adenovir
vector
vaccinologist
alreadi
point
dose
escal
unlik
realist
option
use
human
due
associ
toxic
studi
nonhuman
primat
show
increas
dose
need
achiev
frequenc
transgen
productspecif
cell
compar
obtain
anim
preexpos
effort
focus
combin
vector
vaccin
carrier
primeboost
regimen
repeat
use
vector
test
gener
afford
signific
booster
effect
due
induct
adenovirusneutr
antibodi
first
applic
vector
dna
vaccin
use
prime
shown
increas
adapt
immun
respons
transgen
product
vaccin
reduc
induct
antibodi
respons
adenovir
antigen
nevertheless
dna
vaccin
thu
far
perform
poorli
clinic
trial
effect
prime
human
current
unknown
poxviru
vector
combin
sequenti
adenovir
vector
result
strong
immun
respons
experiment
anim
clinic
trial
combin
vector
antigen
alvac
vector
contempl
nevertheless
experiment
anim
preexpos
viru
develop
dampen
immun
respons
primeboost
regimen
incorpor
vaccin
carrier
vector
coat
peg
multival
hydrophil
polym
base
poli
n
methacrylamid
encapsul
algin
microspher
circumv
effect
virusneutr
antibodi
shown
improv
transduct
cell
mice
circul
antibodi
nevertheless
neither
studi
address
effect
addit
induct
adapt
immun
respons
use
modif
transfer
immunogen
remain
unknown
viral
hexon
main
albeit
exclus
target
adenovirusneutr
antibodi
hexon
swap
tri
succeed
hexon
replac
adenoviru
subgroup
ie
subgroup
c
replac
hexon
hexon
subgroup
result
vector
could
rescu
although
vector
perform
poorli
vivo
attempt
replac
hexon
subgroup
b
e
virus
fail
chimera
show
retard
growth
lower
level
transgen
product
express
compar
origin
vector
one
vector
hexon
replac
hexon
test
mice
interfer
transgen
productspecif
b
cell
activ
presenc
antibodi
hexon
modif
could
rescu
antibodi
respons
nevertheless
remain
significantli
achiev
mice
preexpos
viru
oral
immun
vector
shown
overcom
preexist
neutral
antibodi
viru
nevertheless
alreadi
point
although
oral
immun
induc
adequ
transgen
productspecif
antibodi
titer
rout
immun
thu
far
suboptim
stimul
potent
transgen
productspecif
cell
respons
elicit
system
administr
vector
adenovir
recombin
speci
shown
circumv
vectorspecif
neutral
antibodi
gene
therapi
experi
effort
focus
sever
altern
adenovir
vaccin
carrier
base
virus
isol
chimpanze
assum
adenovir
serotyp
would
close
resembl
wellcharacter
human
serotyp
regard
growth
characterist
influenc
vaccin
yield
tropism
receptor
util
influenc
immunogen
transcomplement
deriv
viru
simian
vector
test
thu
far
ie
also
term
inde
show
compar
yield
upon
propag
hek
cell
indic
could
grow
presenc
viru
use
heterolog
transcomplement
ad
advantag
sequenc
flank
gene
adenoviru
show
limit
homolog
differ
serotyp
risk
contamin
adenovir
vaccin
stock
replicationcompet
viru
aris
upon
homolog
recombin
vaccin
packag
cell
line
thu
virtual
absent
deriv
differ
serotyp
vector
one
virus
ie
viru
test
extens
accord
sequenc
viru
close
relat
subgroup
e
human
adenovirus
amino
acid
level
viru
shown
sequenc
homolog
known
sequenc
adenoviru
human
serotyp
thu
far
partial
sequenc
human
carri
neutral
antibodi
viru
test
chimpanze
sera
antibodi
demonstr
viru
inde
preval
speci
similar
viru
viru
gain
entri
cell
car
thu
tropism
similar
wellstudi
human
viru
viru
show
partial
crossreact
virusneutr
antibodi
viru
thu
appear
belong
serotyp
viru
crossneutr
antibodi
viru
vector
test
transgen
product
express
differ
cell
type
use
exampl
green
fluoresc
protein
transgen
product
vector
express
rabi
viru
glycoprotein
test
stimul
antibodi
respons
vector
express
codonoptim
gag
test
stimul
cell
adapt
immun
respons
assess
narv
mice
well
mice
preexpos
common
human
serotyp
adenoviru
notabl
viru
transgen
express
achiev
simian
vector
compar
vector
cell
type
especi
cell
known
express
car
cell
type
includ
mous
human
dendrit
cell
chimpanzeeorigin
vector
express
less
transgen
product
upon
infect
dendrit
cell
simian
vector
induc
product
high
level
type
interferon
observ
dendrit
cell
transduc
compar
dose
vector
simian
vector
express
rabi
viru
glycoprotein
induc
upon
intramuscular
subcutan
applic
virusneutr
antibodi
protect
mice
challeng
rabi
viru
nevertheless
titer
lower
achiev
compar
dose
vector
simian
vector
elicit
upon
system
immun
antibodi
respons
transgen
product
nearli
exclus
isotyp
vector
induc
mainli
antibodi
also
readili
detect
level
indic
balanc
respons
upon
intranas
applic
simian
vector
vector
induc
compar
titer
antibodi
sera
mucos
surfac
simian
vector
stimul
potent
transgen
productspecif
cell
respons
mice
slightli
superior
achiev
vector
nonhuman
primat
primeboost
regimen
either
two
heterolog
chimpanzeeorigin
vector
vector
follow
chimpanze
origin
vector
result
except
high
frequenc
transgen
product
ie
gag
specif
cell
respons
indic
vector
also
highli
immunogen
larger
speci
importantli
least
mice
transgen
productspecif
b
cell
respons
elicit
chimpanzeeorigin
vector
impair
preexist
immun
common
human
serotyp
adenoviru
transgen
productspecif
cell
respons
come
slight
delay
compar
elicit
vector
slightli
reduc
mice
preexpos
viru
caus
cell
crossreact
adenovir
serotyp
simian
human
origin
presum
elimin
transduc
antigenpres
cell
thu
reduc
antigen
load
viru
lower
seropreval
human
viru
vector
vaccin
construct
vector
shown
distinct
biodistribut
mice
express
vector
main
receptor
upon
intraven
inject
vector
strongli
favor
transduct
liver
cell
observ
upon
applic
vector
neutral
antibodi
viru
inhibit
transduct
cell
vitro
vivo
vector
express
gag
stimul
mice
gagspecif
cell
respons
titrat
vector
comparison
vector
express
transgen
product
show
vector
use
approxim
higher
dose
vector
achiev
compar
frequenc
transgen
productspecif
cell
vector
vector
induc
detect
transgen
productspecif
b
cell
respons
expect
preexist
immun
viru
strongli
reduc
gagspecif
cell
respons
vector
without
affect
vector
effect
low
level
antibodi
found
human
unit
state
human
sera
japan
europ
yet
investig
vector
test
thoroughli
induct
transgen
productspecif
immun
respons
anim
express
transgen
mice
outbreak
new
infecti
diseas
sar
continu
threat
bioterror
increas
pace
research
develop
novel
vaccin
belief
due
versatil
varieti
adenoviru
serotyp
valuabl
tool
develop
vaccin
new
pathogen
vaccin
yet
discov
obstacl
identifi
use
vaccin
carrier
base
recombin
adenoviru
extens
knowledg
biolog
adenoviru
enabl
research
develop
method
overcom
issu
discuss
text
last
evidenc
report
adenovirus
move
forefront
vaccinolog
show
substanti
promis
vehicl
antigen
deliveri
number
vaccin
current
develop
includ
hiv
